Therapeutics News and Research

RSS

Researchers develop new ways for splitting dangerous pair of cancer proteins

A research team led by U of T Mississauga scientists has developed a new way to split up a dangerous pair of cancer proteins, a finding that could ultimately lead to chemotherapy that is more effective and has fewer side effects.

21 Aug 2009

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

21 Aug 2009

Health Canada approves Anika Therapeutics' MONOVISC drug

Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.

21 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Vanderbilt University has been selected as one of 10 centers in the nation to participate in the Chemical Biology Consortium (CBC), a major new initiative to facilitate the discovery and development of new agents to treat cancer.

20 Aug 2009

Institutional investor buys $30 million of convertible stock and warrants in Cell Therapeutics

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.

20 Aug 2009

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fourth quarter and fiscal year ended June 30, 2009.

19 Aug 2009

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009.

19 Aug 2009

Kolltan Pharmaceuticals raises additional $5 million to close Series A financing

Kolltan Pharmaceuticals, Inc. announced today that it has raised an additional $5 million to close its Series A preferred stock financing at $40 million. Participants in the Series A financing, originally announced in January 2009, include Purdue Pharma, L.P., HBM BioCapital L.P., the Pritzker/Vlock family, and other substantial private life science investors.

19 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

Joseph F. Finn, Jr., C.P.A. , announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.

19 Aug 2009

Second BioPharm America partnering event aims to address key industry issues

EBD Group today announced that the second annual BioPharm America™ partnering event, September 16–18 at the San Francisco Marriott, will host some of the biggest names in biotech business who will tackle many of the key issues on the minds of industry executives around the world.

19 Aug 2009

Algos Therapeutics changes name to Algos Preclinical Services

Following a shift in its business model from developing proprietary pain therapy products to pure contract research, Algos Therapeutics has changed its name to Algos Preclinical Services. The company's new tagline, "Expertise in pain. Legendary service. Definitive results. For better quality of life." reinforces its repositioning as the go-to-CRO (Contract Research Organization) for drug discovery and product development.

19 Aug 2009

George Rehm and David Mahoney joins Adamas' Board of Directors

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, the company announced the election of George M. Rehm, Managing Partner of aeris CAPITAL AG, and David L. Mahoney, a private equity investor, to the company's Board of Directors.

19 Aug 2009

New colon cancer target

New research led by scientists at the University of North Carolina at Chapel Hill School of Medicine have found a drug target that suggests a potent way to kill colon cancers that resist current drugs aimed at blocking a molecule found on the surface of cells.

18 Aug 2009

Pharmathene reports Q2 2009 financials

PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2009.

14 Aug 2009

Opexa Therapeutics reports Q2 2009 financials

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2009, and provided details on further developments.

13 Aug 2009

Aryx Therapeutics reports Q2 2009 financials

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided a general business update for the second quarter ended June 30, 2009.

13 Aug 2009

Amsterdam Molecular Therapeutics reports 2009 half year financials

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

13 Aug 2009

Oxygen treatment may speed memory loss associated with Alzheimer's

A 65-year-old women goes into the hospital for routine hip surgery. Six months later, she develops memory loss and is later diagnosed with Alzheimer's Disease. Just a coincidence? Researchers at the University of South Florida and Vanderbilt University don't think so. They suspect that the culprit precipitating Alzheimer's disease in the elderly women may be a routine administration of high concentrations of oxygen for several hours during, or following, surgery - a hypothesis borne out in a recent animal model study.

12 Aug 2009

Therapeutics News and Research

Researchers develop new ways for splitting dangerous pair of cancer proteins

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

Health Canada approves Anika Therapeutics' MONOVISC drug

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Institutional investor buys $30 million of convertible stock and warrants in Cell Therapeutics

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

Kolltan Pharmaceuticals raises additional $5 million to close Series A financing

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

Second BioPharm America partnering event aims to address key industry issues

Algos Therapeutics changes name to Algos Preclinical Services

George Rehm and David Mahoney joins Adamas' Board of Directors

New colon cancer target

Pharmathene reports Q2 2009 financials

Opexa Therapeutics reports Q2 2009 financials

Aryx Therapeutics reports Q2 2009 financials

Amsterdam Molecular Therapeutics reports 2009 half year financials

Oxygen treatment may speed memory loss associated with Alzheimer's

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News